Losartan for Gout Prevention and Uric Acid Lowering
Losartan should be considered as the preferred antihypertensive agent in patients with gout or hyperuricemia, but it is NOT sufficient as primary urate-lowering therapy and cannot replace dedicated urate-lowering treatment like allopurinol or febuxostat.
Primary Recommendation Based on Guidelines
The 2017 EULAR guidelines explicitly recommend that when gout occurs in a patient requiring antihypertensive therapy, consider losartan or calcium channel blockers 1. This is a Grade C recommendation with strong consensus (level of agreement 8.2±0.9). The 2006 EULAR guidelines similarly state that for patients with gout and hypertension, losartan should be considered due to its modest uricosuric effects 2.
The 2020 ACR guidelines conditionally recommend choosing losartan preferentially as an antihypertensive agent when feasible for patients with gout, regardless of disease activity 3. However, they specifically recommend AGAINST adding or switching cholesterol-lowering agents to fenofibrate solely for urate-lowering purposes, emphasizing that medication changes should only occur when benefits exceed risks.
Magnitude of Uric Acid Lowering Effect
Losartan produces a modest reduction in serum uric acid of approximately 0.3 mg/dL (0.29-0.35 mg/dL) compared to placebo 4. This effect is:
- Substantially smaller than dedicated urate-lowering therapies (allopurinol, febuxostat typically lower uric acid by 2-4 mg/dL)
- Insufficient to achieve target serum uric acid <6 mg/dL in most patients with established gout 5
- Clinically relevant primarily for counteracting diuretic-induced hyperuricemia 6, 4
A 2023 analysis from the HEAAL trial demonstrated that high-dose losartan (150 mg/day) reduced serum uric acid by 0.27 mg/dL more than low-dose (50 mg/day), and reduced the incidence of hyperuricemia but not gout attacks 7.
Clinical Algorithm for Use
When to Choose Losartan:
- Patient with gout + hypertension requiring antihypertensive therapy → Switch to or initiate losartan if feasible
- Patient on diuretics who develops gout → Stop diuretic if possible; if antihypertensive still needed, use losartan 1, 2
- Patient with borderline hyperuricemia (serum uric acid 7-8 mg/dL) needing blood pressure control → Losartan is preferred choice 6
When Losartan is NOT Sufficient:
- Established gout with recurrent attacks → Requires dedicated urate-lowering therapy (allopurinol first-line) PLUS losartan for blood pressure 1, 2
- Serum uric acid >8 mg/dL → Requires dedicated urate-lowering therapy; losartan alone will not achieve target <6 mg/dL 5
- Tophaceous gout or chronic arthropathy → Requires aggressive urate-lowering therapy targeting <5 mg/dL; losartan is adjunctive only 1
Important Caveats
Losartan does NOT prevent gout in the primary prevention sense - it modestly lowers uric acid but cannot prevent crystal formation in patients with significant hyperuricemia. The guidelines are clear that allopurinol remains first-line urate-lowering therapy, starting at 100 mg/day and titrating to achieve serum uric acid <6 mg/dL 1, 2.
The uricosuric effect of losartan works by inhibiting URAT1 (urate transporter 1) in the proximal tubule 6. This mechanism is unique among angiotensin receptor blockers - other ARBs like olmesartan do NOT have this effect 8.
Common pitfall: Prescribing losartan and assuming it replaces the need for allopurinol in patients with established gout. This is incorrect - losartan is an adjunctive strategy when blood pressure control is needed, not a substitute for proper urate-lowering therapy 5, 9.
The FDA label for losartan does not include gout or hyperuricemia as approved indications 10 - its use for uric acid lowering is based on guideline recommendations recognizing its pharmacologic properties.